US FDA staff flags risk of low blood sugar for Novo Nordisk`s weekly insulin
Novo Nordisk to discontinue Levemir insulin in U.S. market
Novo's Biologic Xultophy (Degludec, Liraglutide) Receives Approval in the U.S.
Novo's Biologic Ryzodeg (Insulin aspart & insulin degludec ) Receives Approval in the U.S.
Novo's insulin degludec:Liraglutide Receives Approval in the U.S.
Bagsværd, Denmark, 28 April 2022 – Novo Nordisk today announced headline results from the ONWARDS 2 trial, a phase 3a, 26-week efficacy and safety treat-to-target trial investigating once-weekly...
Novo Nordisk Issues Voluntary Nationwide Recall of Levemir®
The primary endpoint, the rate of overall symptomatic hypoglycaemia in the maintenance period of 36 weeks which was tested for superiority, was numerically lower but not statistically significant versus insulin glargine U300.
BARCELONA—Novo Nordisk’s Tresiba is battling it out with Sanofi’s Toujeo in the next-gen insulin category. And while the Danish drugmaker had been hoping to show its contender could top Sanofi’s rival in a head-to-head showdown, it didn't quite get there.
Shareholders in Novo Nordisk accused the diabetes drugmaker of misleading investors about its insulin drug sales in the U.S., filing a securities lawsuit in Danish court that demands roughly $1.75 billion.